It’s been a busy start to the year at Cyprotex. In February, we signed a strategic partnering deal with Cytocentrics to offer a full panel of single ion channel services to complement our existing electrophysiology capabilities. In March, we released our new Chemical and Cosmetics Testing Guide, and we launched an advanced 3D liver model for detecting DILI potential. In April, we published a peer-reviewed publication on our research in the field of mitochondrial toxicity and launched new GLP and OECD-compliant genotoxicity services. Throughout the year, we have been presenting our novel research at conferences such as SOT, BTS and the AAPS/ITC Drug Transporter Workshop.